Direct comparison
IND vs NDA: Regulatory Comparison
Compare FDA IND and NDA submissions under 21 CFR 312 and 314, covering review timelines, clinical phases, statutory goals, and submission requirements.
Written and maintained by CASRAI Editorial Board
Last updated
Ask CASRAI · free to try
Ask about IND vs NDA: Regulatory Comparison
Ask your first 2 questions free below. Subscribers get 150 a day for $29 a month.
An AI assistant specialized in research administration. It cites the sources behind every answer, labels web answers and says when it can't answer.
Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.
Works on this site and inside Claude, Cursor and the AI tools you already use.
Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays free to read, with no account and no card.
How do Investigational New Drug (IND), New Drug Application (NDA) compare side by side?
The table below compares Investigational New Drug (IND), New Drug Application (NDA) across 12 procurement-relevant dimensions, from statutory purpose & exemption through primary regulatory authority.
Side-by-side comparison
| Dimension | Investigational New Drug (IND) | New Drug Application (NDA) |
|---|---|---|
| Statutory Purpose & Exemption | Exempts an unapproved investigational drug from federal prohibitions against interstate shipment (Section 505(i) of the FD&C Act) to permit clinical trials in human subjects. | Requests formal FDA approval to commercially market, distribute, and sell a new molecular entity or formulation in interstate commerce (Section 505(b) of the FD&C Act). |
| Governing Federal Regulation | 21 CFR Part 312 (Investigational New Drug Application). | 21 CFR Part 314 (Applications for FDA Approval to Market a New Drug). |
| Drug Development Phase | Pre-clinical to clinical transition (submitted prior to Phase 1, Phase 2, or Phase 3 human investigations). | Post-clinical transition (submitted after completion of pivotal Phase 3 trials establishing safety and efficacy). |
| Statutory FDA Review Timeline | 30 calendar days from receipt; clinical investigations may proceed automatically on day 31 unless FDA issues a clinical hold. | 6 months for Priority Review or 10 months for Standard Review under PDUFA review performance goals. |
| Primary Submission Forms | Form FDA 1571 (Investigational New Drug Application) and Form FDA 1572 (Statement of Investigator). | Form FDA 356h (Application to Market a New Drug for Human Use). |
| Human Clinical Trial Data | Proposed clinical investigation protocols; no prior human clinical trial data required for initial first-in-human filing. | Complete clinical study reports (CSRs), patient-level datasets (CDISC SDTM/ADaM), and integrated summaries of safety (ISS) and efficacy (ISE). |
| Nonclinical Data Requirements | GLP-compliant pharmacology and toxicology profiles from in vitro and animal models sufficient to demonstrate safety for human exposure. | Full nonclinical safety package, including chronic toxicity, carcinogenicity, mutagenicity, and reproductive/developmental toxicology. |
| Chemistry, Manufacturing & Controls (CMC) | Phase-appropriate CMC data establishing initial drug identity, purity, potency, stability, and safety for trial subjects. | Comprehensive commercial-scale manufacturing validation, batch release data, stability profiles, packaging controls, and proposed commercial specifications. |
| FDA Regulatory Outcome | Application allowed to proceed (passive clearance), clinical hold (partial or complete), or protocol amendment response. | Formal Approval Letter granting commercial marketing rights, or Complete Response Letter (CRL) detailing submission deficiencies. |
| Submission Structure & Format | Electronic Common Technical Document (eCTD) format covering initial Modules 1 to 5. | Full electronic Common Technical Document (eCTD) encompassing comprehensive Modules 1 through 5 with full datasets. |
| Post-Submission Maintenance | Annual Reports (21 CFR 312.33), IND Safety Reports for unexpected serious adverse reactions (21 CFR 312.32), and Protocol Amendments (21 CFR 312.30). | Post-Marketing Safety Reports (21 CFR 314.80), Annual Reports (21 CFR 314.81), REMS assessments, and Post-Marketing Commitments/Requirements (PMR/PMC). |
| Primary Regulatory Authority | US FDA Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER) under 21 CFR 312. | US FDA Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER) under 21 CFR 314. |
Common questions
Common questions about Investigational New Drug (IND) vs New Drug Application (NDA)
Can clinical trials proceed in the US without an active IND?
+
No clinical trial of an unapproved drug or an unapproved use of an approved drug may proceed in the United States without an active IND, unless the investigation meets the specific exemption criteria set out in 21 CFR 312.2(b).
Does the FDA issue a formal approval letter for an IND?
+
The FDA does not issue an approval letter for an IND. Under 21 CFR 312.40(b), an IND goes into effect automatically 30 calendar days after FDA receives the application, unless the agency communicates a clinical hold before the 30-day clock expires.
What is the role of the Common Technical Document (eCTD) in IND and NDA filings?
+
Both INDs and NDAs use the ICH M4 Common Technical Document (eCTD) modular hierarchy. An IND initiates Modules 1 through 5 with early nonclinical and protocol data, whereas an NDA completes all five modules exhaustively with full clinical study reports, patient data, and manufacturing validations.
